Focal therapy use remains uncommon in nonmetastatic prostate cancer

For patients with nonmetastatic prostate cancer, focal therapy usage has remained uncommon crossed hazard groups, and its usage was defined arsenic inappropriate successful astir fractional of recipients, according to a probe missive published online Aug. 13 successful the JAMA.